#36 – Stella K. Vnook, CEO at Likarda

Journey to Leadership: Stella Vnook’s Path to Likarda

Stella Vnook, CEO of Likarda, narrates her fascinating journey from a passionate scientist in clinical oncology to a strategic business leader in biotech. Her transition through various sectors, including marketing, M&A, and corporate strategy, led her back to her roots in science, culminating in her leadership role at Likarda.

Innovating Cell Therapy with Likarda’s Technology

Likarda’s core-shell spherification technology represents a significant innovation in cell therapy. This approach involves creating beads containing millions of cells, ensuring sustained release, viability, and effective treatment delivery. Targeting areas like liver cells and hormone therapy, this technology promises enhanced patient care and practicality.

Partnerships and Future Directions

Vnook highlights Likarda’s approach to partnerships, focusing on collaboration with companies that align with their mission of improving cell therapy and logistics. The company is also gearing up for launching off-the-shelf products for osteoarthritis and developing solutions for more efficient cell transportation.

Navigating the Funding Landscape

The funding landscape, as described by Vnook, is a critical aspect of Likarda’s strategy. From securing support from the Worth family and investors to exploring non-dilutive funding options, Likarda is strategically navigating its way to scale up and achieve its ambitious goals in the field of cell therapy.

Likarda’s Vision and Next Steps

Under Stella Vnook’s leadership, Likarda is poised for significant advancements in cell therapy and regenerative medicine. With plans to secure Series A funding and develop off-the-shelf products, the company is committed to making a substantial impact in improving therapies and patient outcomes.